According to Dynavax Technologies
's latest financial reports the company has $0.74 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $0.74 B | 18.88% |
2022-12-31 | $0.62 B | 14.37% |
2021-12-31 | $0.54 B | 230.81% |
2020-12-31 | $0.16 B | 9.26% |
2019-12-31 | $0.15 B | 3.79% |
2018-12-31 | $0.14 B | -24.14% |
2017-12-31 | $0.19 B | 135.65% |
2016-12-31 | $81.41 M | -58.49% |
2015-12-31 | $0.19 B | 59.9% |
2014-12-31 | $0.12 B | -35.23% |
2013-12-31 | $0.18 B | 51.34% |
2012-12-31 | $0.12 B | 9.8% |
2011-12-31 | $0.11 B | 57.94% |
2010-12-31 | $72.15 M | 96.5% |
2009-12-31 | $36.72 M | -46.38% |
2008-12-31 | $68.47 M | -22.41% |
2007-12-31 | $88.24 M | 21.17% |
2006-12-31 | $72.83 M | -3.03% |
2005-12-31 | $75.11 M | 14.07% |
2004-12-31 | $65.84 M | 126.29% |
2003-12-31 | $29.09 M | -1.06% |
2002-12-31 | $29.41 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $12.69 B | 1,609.55% | ๐บ๐ธ USA |
Amgen AMGN | $10.94 B | 1,374.33% | ๐บ๐ธ USA |
Biogen BIIB | $1.07 B | 44.74% | ๐บ๐ธ USA |
Gilead Sciences GILD | $7.26 B | 878.58% | ๐บ๐ธ USA |
Merck MRK | $7.09 B | 855.54% | ๐บ๐ธ USA |
AstraZeneca AZN | $8.02 B | 980.56% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $5.17 B | 597.15% | ๐ฌ๐ง UK |
Agenus
AGEN | $76.11 M | -89.75% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $3.22 B | 334.59% | ๐ฎ๐ฑ Israel |